[go: up one dir, main page]

RU95122150A - METHOD FOR TREATMENT AND PREVENTION OF ANIMAL SARCOPTOIDOSIS - Google Patents

METHOD FOR TREATMENT AND PREVENTION OF ANIMAL SARCOPTOIDOSIS

Info

Publication number
RU95122150A
RU95122150A RU95122150/13A RU95122150A RU95122150A RU 95122150 A RU95122150 A RU 95122150A RU 95122150/13 A RU95122150/13 A RU 95122150/13A RU 95122150 A RU95122150 A RU 95122150A RU 95122150 A RU95122150 A RU 95122150A
Authority
RU
Russia
Prior art keywords
animal
sarcoptoidosis
prevention
treatment
dose
Prior art date
Application number
RU95122150/13A
Other languages
Russian (ru)
Other versions
RU2112508C1 (en
Inventor
В.Б. Писков
А.С. Пушкарев
Original Assignee
В.Б. Писков
А.С. Пушкарев
Filing date
Publication date
Application filed by В.Б. Писков, А.С. Пушкарев filed Critical В.Б. Писков
Priority to RU95122150A priority Critical patent/RU2112508C1/en
Priority claimed from RU95122150A external-priority patent/RU2112508C1/en
Publication of RU95122150A publication Critical patent/RU95122150A/en
Application granted granted Critical
Publication of RU2112508C1 publication Critical patent/RU2112508C1/en

Links

Claims (2)

1. Способ лечения и профилактики саркоптоидозов животных путем воздействия на их организм акарицидом, отличающийся от известного тем, что, с целью повышения эффективности способа, в качестве акарицида используют 3,5-дийод-3'-хлор-4'-(п-хлорфенокси)-салициланилид в виде раствора парентерально или орально в дозе 8 - 40 мг/кг массы тела животного.1. A method for the treatment and prevention of animal sarcoptoidosis by treating their body with an acaricide, different from the known one, in order to increase the effectiveness of the method, 3,5-diiod-3'-chloro-4 '- (p-chlorophenoxy) is used as an acaricide ) -salicylanilide in the form of a solution parenterally or orally at a dose of 8-40 mg / kg of animal body weight. 2. Способ по п.1, отличающийся тем, что дисалан применяют в дозе 2 - 8 мг/кг в смеси с ивермектином (авермектином) в дозе 0,05 - 0,15 мг/кг или клозантелом в дозе 7 мг/кг массы тела. 2. The method according to claim 1, characterized in that disalan is used at a dose of 2-8 mg / kg in a mixture with ivermectin (avermectin) at a dose of 0.05-0.15 mg / kg or closantel at a dose of 7 mg / kg body.
RU95122150A 1995-12-26 1995-12-26 Method of treatment and prophylaxis of sarcoptoidosis in animals RU2112508C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU95122150A RU2112508C1 (en) 1995-12-26 1995-12-26 Method of treatment and prophylaxis of sarcoptoidosis in animals

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU95122150A RU2112508C1 (en) 1995-12-26 1995-12-26 Method of treatment and prophylaxis of sarcoptoidosis in animals

Publications (2)

Publication Number Publication Date
RU95122150A true RU95122150A (en) 1998-02-27
RU2112508C1 RU2112508C1 (en) 1998-06-10

Family

ID=20175185

Family Applications (1)

Application Number Title Priority Date Filing Date
RU95122150A RU2112508C1 (en) 1995-12-26 1995-12-26 Method of treatment and prophylaxis of sarcoptoidosis in animals

Country Status (1)

Country Link
RU (1) RU2112508C1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8993546B2 (en) 2003-07-12 2015-03-31 Norbrook Laboratories Limited Parasiticidal composition

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2366950C2 (en) * 2007-07-04 2009-09-10 Виктор Антонович Дриняев Method for microdetermination of closantel in plasma, milk, tissues

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8993546B2 (en) 2003-07-12 2015-03-31 Norbrook Laboratories Limited Parasiticidal composition

Similar Documents

Publication Publication Date Title
RU2220723C2 (en) Agent and method for treatment or prophylaxis of arteriosclerosis
KR950002785A (en) Parathyroid hormone and raloxyphene to increase bone mass
RU94041950A (en) Use of compounds of 3-arylhydroxypropylamine order for enuresis treatment
KR880012218A (en) Treatment of Multiple Sclerosis with Calfon Derivatives
RU94034109A (en) AGENT FOR THE TREATMENT OF THE STATE OF ALARM
EE200000309A (en) Compositions and methods for increasing the concentration and / or motility of human sperm
KR960003729A (en) Drugs with antihyperglycemic action
KR950016760A (en) Hemorrhoids Treatment
RU95122150A (en) METHOD FOR TREATMENT AND PREVENTION OF ANIMAL SARCOPTOIDOSIS
RU96120655A (en) COMPOSITION FOR PREVENTION AND TREATMENT OF FLU AND ARVI
KR900701278A (en) Bile acids for the treatment of viral infections
RU96122561A (en) METHOD FOR COMPLEX THERAPY OF DISEASES
FR2734724B1 (en) APPLICATION OF PYRROLIDINE DERIVATIVES TO THE PREPARATION OF DRUGS FOR THE TREATMENT OF ALCOHOLISM
RU2001118219A (en) ANGIOGENESIS INHIBITOR
JPS57112331A (en) Medical composition of ganoderma lucidum component
KR880009656A (en) Treatment or prophylaxis of local periodontal disease
DE3365954D1 (en) The use of alpha, alpha-dialkyl adamanthylethylamines to treat measles
RU96104214A (en) METHOD FOR TREATING TRANSSUDATIVE FORMS OF CENTRAL CHORIORETHINAL DYSTROPHIES
KR880009652A (en) Therapeutic rheumatoid arthritis using 3-5-dichloro methotrexate and compositions useful therein
RU96113185A (en) SOLUTION FOR THE TREATMENT OF DISEASES AND DAMAGE TO KORATAN-S KORGANITSA
RU94002713A (en) Method for treating children possessing elongated qt interval syndrome
KR930019216A (en) Tumor treatment
CA2099667A1 (en) Agent for treating hepatic diseases
RU96122371A (en) METHOD FOR TREATING ENDOGENOUS AND POSTOPERATIVE ANALYSIS
JPS56103114A (en) Drug for osteoporosis comprising 24r- hydroxycholecalciferol